Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis
Palisade Bio Launches New Corporate Branding and Reiterates Commitment to Advancing Next-Generation Precision Therapies
Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient Stratification
Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]